Skip to content

Myriad Genetics MYGN Investing Cash Flow

Investing Cash Flow at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
-$322.1M+4.1%
Quest Diagnostics logo
Quest DiagnosticsDGX
-$152M-32.2%
NeoGenomics logo
NeoGenomicsNEO
-$5M-240%
Veracyte logo
VeracyteVCYT
-$127.96M-147%
Guardant Health logo
Guardant HealthGH
$699.42M+131%
Natera, Inc. logo
Natera, Inc.NTRA
-$32.14M-91.1%

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's investing cash flow?
Myriad Genetics (MYGN) reported investing cash flow of -$6.5M in Q1 2026.
How has Myriad Genetics's investing cash flow changed year-over-year?
Myriad Genetics's investing cash flow increased by 21.7% year-over-year, from -$8.3M to -$6.5M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.